Market Overview

OrthoPediatrics Could Win By Tapping A Massive, Underserved Market, Says Stifel

Share:
OrthoPediatrics Could Win By Tapping A Massive, Underserved Market, Says Stifel
Related KIDS
The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares
The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage
FDA clears OrthoPediatrics' scoliosis device for smaller stature patients (Seeking Alpha)

Orthopediatrics Corp (NASDAQ: KIDS) is poised to achieve strong top-line growth due to its exclusive focus on the sizeable and largely underserved $2.5 billion pediatric orthopedic market, according to Stifel. 

Stifel initiated coverage of Orthopediatrics with a Buy rating and a $23 price target for the shares. The valuation represents a 5.5 times enterprise value to revenue multiple, applied to Stifel's 2019 revenue estimate for Orthopediatrics of $63.6 billion and discounted 10 percent to the end of 2018.

The pediatric orthopedic market, including trauma and deformity, complex spine and sports medicine, offers the most comprehensive and still-expanding portfolio of pediatric orthopedic implants and instruments to treat a wide array of orthopedic conditions, said analyst Rick Wise

Capitalizing on this opportunity, Wise said the firm can deliver top-line CAGR in the solid high teens, suggesting revenues that would icrease from an estimated $45 million this year to $98.5 million in 2022. This would put Orthopediatrics above the average revenue growth among its peers. 

"A still-expanding portfolio of pediatric orthopedic implants plus post-IPO capital and subsequent investment in growth driving instrument sets, as well as the concentrated pool of pediatric orthopedic surgeons, should help the company accelerate growth and further penetrate the sizable pediatric orthopedic market," Wise said. (See Wise's track record here.) 

OrthoPediatrics sells the broadest offering of implants and instruments designed specifically for children, offering 21 surgical systems, Wise said. Over time, the company's top-line growth will accelerate, fueled by new product introductions and entry into new pediatric orthopedic market opportunities, the analyst said. 

Given that pediatric orthopedic surgeons are generalists treating a wide range of conditions, surgeons represent a single customer call point for Orthopediatrics — one that utilizes the company's entire portfolio, Wise said. 

Related Link: 

FDA's 60-Day Extension For Medical Device Defects Not Likely Obstructive To Public Health

Latest Ratings for KIDS

DateFirmActionFromTo
Nov 2017BTIG ResearchInitiates Coverage OnBuy
Nov 2017William BlairInitiates Coverage OnOutperform
Nov 2017Stifel NicolausInitiates Coverage OnBuy

View More Analyst Ratings for KIDS
View the Latest Analyst Ratings

Posted-In: Matthew Blackman OrthopediatricsAnalyst Color Health Care Price Target Initiation Analyst Ratings General Best of Benzinga

 

Related Articles (KIDS)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
AAPLWedbushInitiates Coverage On310.0
DHTJP MorganUpgrades0.0
DISBarclaysUpgrades130.0
DXCMGoldman SachsUpgrades125.0
ORLYJP MorganUpgrades398.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Ackman Addresses Chipotle Issues

Upcoming Earnings: Snap To Report Q3 Results Tomorrow After The Close